Alliance Pharma plc
Climate Impact & Sustainability Data (2022, 2023)
Reporting Period: 2022
Environmental Metrics
Total Carbon Emissions:48,025 tCO2e (2022)
Scope 1 Emissions:22 tCO2e (2022)
Scope 2 Emissions:50 tCO2e (2022)
Scope 3 Emissions:47,973 tCO2e (2022)
Carbon Intensity:279 tCO2e per £m of revenue (2022)
ESG Focus Areas
- People
- Planet
- Product
Environmental Achievements
- Offset Scope 1 & 2 UK emissions for 2021
- 65% reduction in Scope 1 & 2 emissions (versus 2018 baseline) by 2025 target set
- Net zero (90% absolute reduction) by 2030 target set for Scope 1 & 2 emissions
Social Achievements
- 80 new heads brought into the business in 2022 – 18 of which were in newly created roles
- New UK graduate and industry placement schemes rolled out
- High levels of employee engagement maintained with increased GPTW survey participation and trust index ratings; additional certifications achieved in US and France
- First all-employee conference held
- More targeted approach to online compliance training, driving an increase in course completion rates
- Compliance training provision further enhanced through partnering with new external providers
- Partner code of conduct published
Governance Achievements
- Integrated climate governance into existing corporate governance structures
- Created a stand-alone climate risk management framework and integrated it into wider business risk management processes
Climate Goals & Targets
Medium-term Goals:
- Achieve net zero (90% absolute reduction) in Scope 1 & 2 emissions by 2030
- Set targets for specific categories of Scope 3 emissions
Short-term Goals:
- Achieve a 65% reduction in Scope 1 & 2 emissions (versus 2018 baseline) by 2025
Environmental Challenges
- Reducing the environmental impact of product packaging (particularly blister packs containing non-recyclable PVC)
- Developing Scope 3 emissions reduction targets
- Climate-related risks impacting operations and supply chain (flooding, heatwaves, wildfires, sea level rise, water stress)
- Transition risks (increased regulation, carbon pricing, changing consumer preferences, etc.)
Mitigation Strategies
- Initiated pilot projects to explore more sustainable packaging options (plastic tubes, rigid packaging, blister packs)
- Embedding ownership of product-related emissions within functional areas
- Methodology improvements to increase accuracy of emissions measurement
- Climate scenario analysis and risk assessment to understand climate-related risks
- Developing relationships with partners to support knowledge sharing on climate risks and opportunities
- Extending climate risk analysis to other key partners in the value chain
- Setting Scope 1 & 2 emissions targets
Supply Chain Management
Responsible Procurement
- Partner code of conduct published
- Obtaining confirmation from CMOs that they comply with ethical standards
- Tightening processes around modern slavery
Climate-Related Risks & Opportunities
Physical Risks
- Flooding
- Heatwaves/extreme heat
- Wildfires
- Rising mean temperatures
- Sea level rise
- Water stress
Transition Risks
- Increased regulation due to climate change
- Increase in carbon pricing
- Mandates on and regulation of existing products and services
- Increased cost of energy and materials
- Changing consumer preferences
- Increased stakeholder concern damaging reputation
- Substitution of existing products with lower emissions alternatives
- Costs to transition to lower emissions technology
Opportunities
- Development of new products or services
- Use of lower-emission sources of energy
Reporting Standards
Frameworks Used: TCFD
Reporting Period: 2023
Environmental Metrics
Total Carbon Emissions:50,138 tCO2e/year (Scope 1 & 2: 59 tCO2e)
Scope 1 Emissions:0 tCO2e/year
Scope 2 Emissions:59 tCO2e/year
Scope 3 Emissions:50,125 tCO2e/year
Renewable Energy Share:100% (UK and Germany)
Carbon Intensity:0.81 tCO2e per £m of revenue (2023)
ESG Focus Areas
- People
- Planet
- Product
Environmental Achievements
- 48% reduction in Scope 1 and 2 emissions (versus 2018 baseline), on track to meet interim 65% reduction target by 2025 and achieve net zero in 2030. Scope 3 emissions target set to achieve net zero by 2044 (versus 2022 baseline), with an interim reduction target of 25% by 2030.
- Nizoral™ manufacturing moved from Belgium to Thailand driving cost savings, improving on-time-in-full order delivery and reducing carbon emissions.
Social Achievements
- Re-certified as a Great Place To Work® in UK, US, China and Singapore.
- Launched our Employee Code of Conduct, continued to embed our Partner Code of Conduct and strengthened our suite of policy documents.
- Introduced a new, more comprehensive programme of online compliance training to upskill our employees and contractors.
- Entered a three-year partnership with the social enterprise Slave Free Alliance (“SFA”) to safeguard individuals across our business from modern slavery and human trafficking, including those in our supply chain.
Governance Achievements
- Strengthened Board of Directors with appointment of Jeyan Heper, Martin Sutherland, Richard McKenzie and Eva-Lotta Sjöstedt. Post year end appointments of new Independent Chair, Camillo Pane and new CEO, Nick Sedgwick.
- Successful appeal of Competition and Markets Authority decision clearing Alliance, Peter Butterfield and John Dawson (former CEOs) of any wrongdoing.
Climate Goals & Targets
Long-term Goals:
- Achieve net zero Scope 3 emissions by 2044
Medium-term Goals:
- Achieve 65% reduction in absolute Scope 1 and 2 emissions by 2025 (versus 2018 baseline)
- Achieve 25% reduction in absolute Scope 3 emissions by 2030 (versus 2022 baseline)
- Achieve net zero Scope 1 and 2 emissions by 2030
- Achieve 10% of Consumer Healthcare sales through products developed on our I&D platform within the next five years
Short-term Goals:
- Reduce water consumption
- Reduce waste
- Develop sustainable packaging strategy with KPIs
- Launch new packaging for Nizoral™ Derma Daily
Environmental Challenges
- Challenging H1 performance due to unexpected regulatory issues causing manufacturing delays in certain smaller products and Amberen™ sales hampered by industry-wide challenges on Amazon.
- Amberen™ revenues weaker than anticipated.
- Less favourable product mix and increase in warehouse and distribution costs impacting gross profit growth.
- Counterfeiting and illicit trade of Kelo-Cote™ in China.
- Regulatory transition from the European Medical Device Directive (“MDD”) to the Medical Device Regulation (“MDR”) impacting supply of certain products.
Mitigation Strategies
- Colleagues worked hard to address regulatory issues to ensure all products were back in stock by year-end.
- Strong consumer demand for Kelo-Cote™ drove restocking in H2 and consumer activation campaigns delivered market share gains for Nizoral™.
- Strengthening internal and external capabilities in ecommerce and digital marketing to mitigate future problems on Amazon.
- Substantially reduced counterfeiting of Kelo-Cote™ in China through security measures.
- Painstaking work from cross-functional team to resolve MDR transition issues, with all affected products back in stock.
- Robust control of actively managed costs decreased operating costs by 5%.
Supply Chain Management
Supplier Audits: 93% of CMOs managed by our sourcing team have either signed up to our Partner Code of Conduct or provided us with a copy of their equivalent code.
Responsible Procurement
- Partner Code of Conduct
- Slave Free Alliance partnership
- Modern Slavery Statement
- Three-year anti-slavery strategy and action plan
- Supplier lifecycle due diligence review
Climate-Related Risks & Opportunities
Physical Risks
- Increased frequency and severity of flooding
Transition Risks
- Regulatory changes
- Market shifts towards sustainable products
Opportunities
- Use of lower-emission energy sources
- Increased demand for sustainable products and services
- Enhanced reputation as a market leader in climate action
Reporting Standards
Frameworks Used: TCFD
Certifications: Great Place To Work®
Sustainable Products & Innovation
- New packaging for Nizoral™ Derma Daily
Awards & Recognition
- Best communication of Sustainability in the small cap category from the IR Society